| Vivos Therapeutics, Inc. (VVOS) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2021-Mar-31 | 2020-Dec-31 | ||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q1-FY2021 | Q4-FY2020 | ||||||||||||||||||||||||||||||||||||||
| Price to Sales | .69x | .59x | 1.04x | 1.34x | 1.29x | 1.18x | 1.37x | .61x | .51x | .99x | |||||||||||||||||||||||||||||||||||||||
| Price to Book | - | - | - | 9.19x | 4.06x | 3.92x | 2.59x | 1.16x | 1.14x | 22.71x | 2.41x | 2.02x | 6.51x | 7.84x | 8.52x | ||||||||||||||||||||||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | 1.06x | .90x | .82x | .61x | .48x | .50x | .60x | .95x | .96x | .65x | .35x | .33x | 1.22x | ||||||||||||||||||||||||||||||||||||
| Current Ratio | .24x | .78x | 1.05x | .77x | 1.50x | 1.44x | 1.18x | .45x | .34x | .80x | 2.29x | 2.61x | .22x | ||||||||||||||||||||||||||||||||||||